Home > > > > > Report Detail

T cell lymphoma - Pipeline Insight, 2021

Publisher Name :
Date: 31-May-2021
No. of pages: 200
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "T cell lymphoma - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in T cell lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

T cell lymphoma Understanding

T cell lymphoma: Overview

T-cell lymphomas represent a diverse group of non-Hodgkin lymphomas of mature T-cell origin that generally are associated with unfavorable prognosis. However, recent breakthroughs have allowed a better understanding of pathogenetic mechanisms of T-cell lymphomagenesis and uncovered molecular alterations that can be assessed using new biomarker approaches and can be specifically targeted with documented improvements in outcomes. A particularly promising area in which significant progress has been made is the role of epigenetic alterations, including dysregulation of DNA methylation and histone modifications, in T-cell lymphomagenesis.

T-cell lymphomas encompass a group of heterogeneous diseases accounting for less than 10% of non-Hodgkin lymphomas. With the exception of ALK positive anaplastic large cell lymphoma, T-cell lymphomas also tend to be more clinically aggressive than their B-cell counterparts.

In spite of substantial advances in the treatment of lymphoma in general, the prognosis of patients with relapsed or treatment-refractory T-cell lymphoma remains poor, necessitating the development of novel approaches and therapies. Epigenetic dysregulation has a potential role in initiating and promoting a wide variety of malignancies and is observed in both B-cell and T-cell lymphomas.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence T cell lymphoma R&D. The therapies under development are focused on novel approaches for T cell lymphoma.

T cell lymphoma Emerging Drugs Chapters

This segment of the T cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

T cell lymphoma Emerging Drugs

- SGX-301: Soligenix

SGX301 is a photodynamic therapy using synthetically manufactured hypericin in an ointment combined with visible fluorescent light. Hypericin is one of the most photoactive compounds known - it is easily activated with relatively low energy light. This makes it ideal for photodynamic therapy because it can be activated with fluorescent light, instead of UV A or UV B light, which are associated with increased cancer risks.

Synthetic hypericin, the active ingredient in SGX301, tends to accumulate in T-cells. Once the hypericin is in the T-cells, it can be activated by safe, visible fluorescent light. When synthetic hypericin is activated it creates oxygen radicals which subsequently cause cellular toxicity, killing the targeted T-cells. It is currently in Phase III stage of development for Cutaneous T-cell lymphoma and is being developed by Soligenix.

- SP-02: Solasia Pharma

SP-02 (Darinaparsin) is a novel mitochondrial-targeted agent (organic arsenic) being developed for the treatment of various hematologic and solid cancers. In a Phase II study in the U.S. Intravenous darinaparsin demonstrated evidence of clinical activity in malignant lymphoma, and in particular peripheral T-cell lymphoma (PTCL). Darinaparsin was granted Orphan Drug Designation in the U.S. and Europe as a treatment of PTCL and Solasia intends to seek similar status in Japan.

It is currently in Phase III stage of development for the treatment of peripheral T-cell lymphoma (PTCL) and is being developed by Solasia Pharma.

Further product details are provided in the report……..

T cell lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different T cell lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players working on T cell lymphoma

There are approx. 100+ key companies which are developing the T cell lymphoma. The companies which have their T cell lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Soligenix.

- Phases

DelveInsight's report covers around 120+ products under different phases of clinical development like

- Late-stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

T cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Infusion

- Intradermal

- Intramuscular

- Intranasal

- Intravaginal

- Oral

- Parenteral

- Subcutaneous

- Topical

- Molecule Type

Products have been categorized under various Molecule types such as

- Vaccines

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

T cell lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses T cell lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T cell lymphoma drugs.

T cell lymphoma Report Insights

- T cell lymphoma Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

T cell lymphoma Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

- How many companies are developing T cell lymphoma drugs?

- How many T cell lymphoma drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for T cell lymphoma?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the T cell lymphoma therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for T cell lymphoma and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Celgene

- CSPC ZhongQi Pharmaceutical Technology

- Jazz Pharmaceuticals

- Genor Biopharma

- Eisai

- Soligenix

- Elorac

- Shanghai YingLi Pharmaceutical

- ViGenCell

- Daiichi Sankyo

- Chia Tai Tianqing Pharmaceutical Group

- BeiGene

- Kura Oncology

- Solasia Pharma

- Innovent bilogics

- Nanjing Sanhome Pharmaceutical

- Rhizen Pharmaceuticals SA

- 4SC AG

- Precision Bioscience

- Millennium Pharmaceuticals, Inc.

- Innate Pharma

- ImmuneOncia Therapeutics

- HUYA Bioscience International

- CerRx, Inc.

- Shandong New Time Pharmaceutical Co., LTD

- Verastem, Inc.

- Janssen Research & Development

- Celleron Therapeutics

- CStone Pharmaceuticals

- Viridian Therapeutics

- Hebei Senlang Biotechnology Inc.

- Galderma

- Seagen

- Bioniz Therapeutics

- Almirall

- Dizal Pharmaceuticals

- Pfizer

- Hoffmann-La Roche

- Affimed GmbH

- Sorrento Therapeutics

- Merck Sharp & Dohme

- Eli Lilly and Company

- Bayer

- Genzyme

- Portola Pharmaceuticals

- Onyx Pharmaceuticals

- AstraZeneca

- Astex Therapeutics

- Yake Biotechnology Ltd.

- Aileron Therapeutics

- Akeso Pharmaceuticals, Inc.

- Viracta

- Otsuka Pharmaceutical

- VelosBio

- Trillium Therapeutics Inc.

- Mundipharma-EDO GmbH

- TG Therapeutics, Inc.

- PersonGen BioTherapeutics (Suzhou) Co

- Sorrento Therapeutics

- Oncotartis

- Myeloid Therapeutics

- Bio-Path Holdings, Inc.

- Legend Biotech

- Immune Cell

- Genzada Pharmaceuticals

- Gracell

- CRISPR Therapeutics

- Corvus Pharmaceuticals, Inc.

- Rafael Therapeutics

- Antengene Corporation

- Viridian Therapeutics

- iCell Gene Therapeutics

- Tessa Therapeutics

- Boryung Pharmaceutical Co., Ltd

- Bristol-Myers Squibb

- Antengene Corporation

- Amgen

- ADC Therapeutics S.A.

- Legend Biotech USA Inc

- VidacPharma

- Medc Biopharma

- Scopus Biopharma

- Almirall

- Brickell Bio

- AVM Biotechnology

- Autolus

- Applied Therapeutics

- TetraLogic Pharmaceuticals

- Moleculin Biotech

Key Products

- Lenalidomide

- Mitoxantrone Hydrochloride

- JZP-458

- GB226

- Denileukin diftitox

- SGX 301

- Naloxone Hydrochloride

- YY-20394

- VT-EBV-N

- Valemetostat Tosylate

- TQ-B3525

- TQ-B3101

- Tislelizumab

- Tipifarnib

- SP-02L

- SP-02

- Sintilimab

- SHC014748M

- SGN-35

- RP6530

- Resminostat

- Pembrolizumab

- PBCAR20

- Nivolumab

- MLN 9708

- Letermovir

- Lacutamab

- IPH4102

- IMC-001

- HBI-8000

- Fenretinide

- F520

- Duvelisib

- DS-3201

- Daratumumab

- CXD 101

- CS1001

- Cobomarsen

- CD7 CAR-T

- CD11301

- Brentuximab Vedotin

- BNZ132-1-40

- BNZ1

- AZD4205

- Azacytidine

- Avelumab

- Atezolizumab

- AFM13

- STI-3031

- MK-3475

- LY3039478

- Durvalumab

- Copanlisib

- Clofarabine

- Cerdulatinib (PRT062070)

- carfilzomib

- AZD5991

- ASTX660

- ALRN-6924

- AUTO4

- AK104

- Nanatinostat + Valganciclovir

- ASTX660

- ARGX-110

- VLS-101

- TTI-621

- Tinostamustine

- TGR-1202

- Temsirolimus

- Sofusa anti-PD1

- SEA-TGT

- OT-82

- MT-101

- L-Bcl-2 antisense oligonucleotide

- LB1901

- ICAR30 T cells

- GZ17-6.02

- GC027

- CTX130

- CPI-818

- CPI-613/Devimistat

- Cobomarsen

- CD4 CAR T cells

- CD30.CAR-T

- BR101801

- BMS-906024

- AZD4573

- ATG-010

- AMG 319

- ADCT-301

- LB1901

- CD7-CART

- VDA-1102

- MDC 2021

- MDC 2020

- CO-sTiRNA

- CD-7 UCART

- BNZ1

- BBI-3000

- AVM-0703

- Auto 5

- AT-104

- Lorlatinib

- CPX-351

- SHP-141

- WP1220

?

T cell lymphoma - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
T cell lymphoma: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
T cell lymphoma- DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• T cell lymphoma companies' collaborations, Licensing, Acquisition -Deal Value Trends
T cell lymphoma Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
SGX-301: Soligenix
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
AFM13: Affimed
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
MT-101: Myeloid Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
AT-104: Applied Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..

Inactive Products
• Comparative Analysis
T cell lymphoma Key Companies
T cell lymphoma Key Products
T cell lymphoma- Unmet Needs
T cell lymphoma- Market Drivers and Barriers
T cell lymphoma- Future Perspectives and Conclusion
T cell lymphoma Analyst Views
T cell lymphoma Key Companies
Appendix


List of Tables

Table 1 Total Products for T cell lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products


List of Figures

Figure 1 Total Products for T cell lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global 5-Fluorouracil Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 76
    The global 5-Fluorouracil market was valued at US$ 283 million in 2023 and is anticipated to reach US$ 487.9 million by 2030, witnessing a CAGR of 4.3% during The forecast period 2024-2030. North American market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by ......
  • Global Carboplatin Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79
    The global Carboplatin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % d......
  • Global Neutropenia Drugs Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 96
    The global Neutropenia Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated to increa......
  • Global Small Molecule Cancer Drug Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Small Molecule Cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated ......
  • Global Capecitabine Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 80
    Capecitabine is an orally-administered chemotherapeutic agent used in The treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in The tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blo......
  • Global Oxaliplatin Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 104
    Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy The third stage colon cancer after resecting primary tumor completely. In this report, only The finished drug is covered, exclude API. The global Oxaliplatin market was valued at US$ 897.5 million in 2023 and is anticipated to reach US$ 1641.5 million by 2030, witnessing a CAGR of 8.9% duri......
  • Global Cancer Treatment Drugs Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 158
    According to our LPI (LP Information) latest study, the global Cancer Treatment Drugs market size was valued at US$ 174990 million in 2023. With growing demand in downstream market, the Cancer Treatment Drugs is forecast to a readjusted size of US$ 322540 million by 2030 with a CAGR of 9.1% during review period. The research report highlights the growth potential of the global Cancer Treatment Drugs market. Cancer Treatment Drugs are expected to show stable growth in the future market. H......
  • Global Capecitabine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93
    According to our LPI (LP Information) latest study, the global Capecitabine market size was valued at US$ 1003.9 million in 2023. With growing demand in downstream market, the Capecitabine is forecast to a readjusted size of US$ 975.1 million by 2030 with a CAGR of -0.4% during review period. The research report highlights the growth potential of the global Capecitabine market. Capecitabine are expected to show stable growth in the future market. However, product differentiation, reducin......
  • Global Methotrexate Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95
    According to our LPI (LP Information) latest study, the global Methotrexate market size was valued at US$ 506 million in 2023. With growing demand in downstream market, the Methotrexate is forecast to a readjusted size of US$ 613.9 million by 2030 with a CAGR of 2.8% during review period. The research report highlights the growth potential of the global Methotrexate market. Methotrexate are expected to show stable growth in the future market. However, product differentiation, reducing co......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs